National Health Act (Pharmaceutical Benefits – Early Supply) Amendment November 2009 - specification under subsection 84AAA(2) (No. PB 103 of 2009)

Administered by Department of Health, Disability and Ageing

Legislation au F2009L04036 Not in force Legislative Instrument

Legislation content

 

EXPLANATORY STATEMENT

 

NATIONAL HEALTH ACT 1953

 

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS – EARLY SUPPLY) AMENDMENT NOVEMBER 2009 - SPECIFICATION UNDER SUBSECTION 84AAA(2)

 

INSTRUMENT NUMBER PB 103 OF 2009

 

Purpose and operation

Part VII of the National Health Act 1953 (the Act) is the legislative basis of the Pharmaceutical Benefits Scheme (PBS) by which the Commonwealth provides reliable, timely, and affordable access to a wide range of medicines for all Australians.

 

Subsection 85(1) provides that benefits are to be provided by the Commonwealth in accordance with Part VII in respect of pharmaceutical benefits.

 

Drugs and medicinal preparations to which Part VII applies are declared by the Minister by legislative instrument to be so under subsection 85(2).  These are listed drugs as defined in subsection 84(1).

 

Subsection 85(3) authorises the Minister by legislative instrument to determine by reference to strength, type of unit, size of unit, or otherwise, the form or forms of a listed drug.  Subsection 85(5) authorises the Minister by legislative instrument to determine the manner of administration of a form of a listed drug where the form has been determined under subsection 85(3).  Subsection 85(6) authorises the Minister by legislative instrument to determine a brand of a pharmaceutical item.

 

These determinations govern what constitutes a pharmaceutical benefit (defined in subsection 84(1)) under part VII of the Act.

 

Paragraph 85A(2)(a) authorises the Minister to determine the maximum quantity or number of units that may, in one prescription, be directed to be supplied for all purposes or for a particular purpose.  Paragraph 85A(2)(b) authorises the Minister to determine the maximum number of occasions on which the supply may, in one prescription, be directed to be repeated for all purposes or a particular purpose.

 

Paragraph 84C(4A)(a) of the Act refers to repatriation pharmaceutical benefits supplied under the scheme established under section 91 of the Veterans’ Entitlements Act 1986 or supplied in accordance with a determination made under paragraph 256(1)(c) of the Military Rehabilitation and Compensation Act 2004.

 

Subsection 84AAA(1) of the Act provides that a supply of a pharmaceutical benefit to a person (whether or not that supply is a supply of a kind described in paragraph 84C(4A)(a)) is an early supply of a specified pharmaceutical benefit if:

  • The supply is made within 20 days after the day of a previous supply of the same pharmaceutical benefit to the person (whether or not the previous supply is a supply of a kind described in paragraph 84C(4A)(a));
  • The pharmaceutical benefit is specified in an instrument under subsection 84AAA(2); and
  • The supply does not result from a prescription originating from a hospital or a day hospital facility.

 

The early supply of a specified pharmaceutical benefit includes a supply of a pharmaceutical benefit specified in the instrument, as either a pharmaceutical benefit or a repatriation pharmaceutical benefit within 20 days of a previous supply of the same pharmaceutical benefit (as either a pharmaceutical benefit or a repatriation pharmaceutical benefit) to the same person.  The repatriation pharmaceutical benefits supplied under the Repatriation Pharmaceutical Benefits Scheme (RPBS) which are subject to the provisions for early supply of a specified pharmaceutical benefit are those where the repatriation pharmaceutical benefit is the same as a specified pharmaceutical benefit for supply under the PBS.

 

‘Hospital’ is defined in the subsection 3(1) of the Health Insurance Act 1973 to mean a recognised hospital, a private hospital, or a hospital that is declared by the Minister to be a hospital for the purposes of that definition.  ‘Day hospital facility’ is defined in subsection 4(1) of the National Health Act 1953.

 

Subsections 84C(4) and 84C(4A) of the Act regulate the supply or repeated supply of pharmaceutical benefits and repatriation pharmaceutical benefits which are be taken into account in totalling amounts charged for the purpose of demonstrating eligibility for a safety net concession card or safety net entitlement card.

 

Subsection 84C(4AA) of the Act provides that the amount charged for an early supply of a specified pharmaceutical benefit must not be taken into account when determining eligibility for a concession card or entitlement card, if the supply is an early supply of a pharmaceutical benefit specified in the instrument and the supply is not a supply of an out-patient medication.  Out-patient medication is defined in subsection 84(1) of the Act to mean a drug or medicinal preparation supplied through the out-patient department of a public hospital.

 

Subsection 87(2) of the Act sets out the amounts to be charged to patients for the supply of pharmaceutical benefits.  These provisions form the basis for the patient charges which apply for general benefit prescriptions (currently up to $32.90), concessional benefit prescriptions (currently $5.30), concession card prescriptions (currently $5.30), and entitlement prescriptions (free).  The provisions also set the charges for prescriptions which are an early supply of a pharmaceutical benefit.  Prescriptions for repatriation pharmaceutical benefits are treated as for concessional benefit prescriptions and entitlement prescriptions.

 

Section 99 of the Act regulates the amounts that pharmacists and medical practitioners who are approved under the Act to supply pharmaceutical benefits, are entitled to be paid by the Commonwealth for supplying those benefits.  This includes the amount to be paid for prescriptions which are an early supply of a pharmaceutical benefit.

 

This legislative instrument is made under subsection 84AAA(2) of the Act. Subsection 84AAA(2) of the Act provides that the Minister may specify, by legislative instrument, pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act.  Subsection 84AAA(3) provides that the instrument may specify a pharmaceutical item by reference to the circumstances in which a pharmaceutical benefit that has the pharmaceutical item is supplied or any other circumstances in relation to a pharmaceutical benefit that has the pharmaceutical item.

 

The pharmaceutical items specified in the Instrument are specified by the Minister who can take into account the advice of the Pharmaceutical Benefits Advisory Committee (PBAC).  The PBAC is the independent expert body, established by section 100A of the Act, which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.  PBAC members are selected from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions.  Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC.

 

Section 101 of the Act sets out the functions of the PBAC in relation to making recommendations and providing advice to the Minister regarding the medicines to be declared as pharmaceutical benefits under Part VII of the Act, and any other matter concerning Part VII of the Act referred to the PBAC by the Minister.

 

Subsection 101(3AA) requires the PBAC to make recommendations to the Minister about what should be specified in an instrument made under 84AAA(2).

 

This Instrument was made on 16 October 2009 and commences on 1 November 2009.

 

This Instrument is a legislative instrument for the purposes of the Legislative Instruments Act 2003.

 

Details of the Instrument are set out in Attachment 1.

 

Effect of the Instrument

This Instrument amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - Specification Under Subsection 84AAA(2), PB No. 30 of 2009.  The Instrument amends the list of items specified under subsection 84AAA(2).  Details of the changes effective from 1 November 2009 are set out in Attachment 2.  Additional items and circumstances effective from 1 November 2009 are described in Table 1, changes to existing items and circumstances are described in Table 2, and omitted items and circumstances are described in Table 3.

 

Consultations

Consultation regarding implementation of the arrangements for early supply of specified pharmaceutical benefits occurred with Medicare Australia, the Department of Veterans’ Affairs, the Medical Software Industry Association (MSIA), and peak pharmacy organisations (including the Pharmacy Guild of Australia, the Pharmaceutical Society of Australia, the Australian Association of Consultant Pharmacy, and the Society of Hospital Pharmacists of Australia).  The PBAC has provided advice on which pharmaceutical benefits should be specified in the Instrument.


ATTACHMENT 1

Section 1: provides that the name of the Instrument is the National Health (Pharmaceutical Benefits – Early Supply) Amendment November 2009 - specification under subsection 84AAA(2) and that the Instrument may also be cited as
No. PB 103 of 2009.

 

Section 2: provides that the Instrument commences on 1 November 2009.

 

Section 3: provides that this Amendment amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - specification under subsection 84AAA(2), No. PB 30 of 2009.

 

Schedule 1:  specifies the pharmaceutical items in the pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act by reference to the drug or medicinal product as declared under subsection 85(2), the form (strength, type, size, etc.) as determined under subsection 85(3), manner of administration as determined under subsection 85(5), maximum quantity or number of units as determined under paragraph 85A(2)(a); maximum repeats as determined under paragraph 85A(2)(b), and any other circumstances that apply under paragraph 84AAA(3)(b) of the Act.

 

ATTACHMENT 2

 

 

Table 1.  Forms added

Ezetimibe with Simvastatin

Tablet 10 mg-10 mg

Tablet 10 mg-20 mg

Valsartan with hydrochlorothiazide

Tablet 320 mg-12.5 mg

Tablet 320 mg-25 mg

 

 

Table 2.  Form Descriptions changed

 From: To:

Etanercept

Injection 50 mg in 1 mL single use injection pen, 4

Injection 50 mg in 1 mL single use auto-injector, 4

 

 

Table 3.  Deletions

Listed Drug

Form (strength, type, size, etc.)

Manner of Administration

Maximum quantity or # of units

Maximum repeats

Lansoprazole

Capsule 30 mg

Oral

30

5

Sachet containing granules for oral suspension, 30 mg per sachet

Oral

28

5

 

Overview

The National Health (Pharmaceutical Benefits – Early Supply) Amendment November 2009, specified under subsection 84AAA(2) of the National Health Act 1953, was enacted to address the gap in the Pharmaceutical Benefits Scheme (PBS) regarding the early supply of certain pharmaceutical benefits. This legislative instrument, made under subsection 84AAA(2), aims to specify the pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act, thereby regulating the early supply of these benefits and ensuring they do not impact eligibility for safety net concession cards. The National Health Act, enacted by the Parliament of Australia, provides the legislative basis for the PBS, which offers reliable, timely, and affordable access to a wide range of medicines for all Australians. The policy objective is to manage the supply of pharmaceutical benefits more effectively by preventing the early supply of specified items, which would otherwise interfere with the calculation of safety net entitlements. The changes introduced by this legislative instrument, effective from 1 November 2009, include the addition of new pharmaceutical items, modifications to existing items, and the removal of certain items from the list, all based on advice from the Pharmaceutical Benefits Advisory Committee (PBAC).

Scope and Application

The National Health (Pharmaceutical Benefits – Early Supply) Amendment November 2009 - Specification Under Subsection 84AAA(2) Instrument is a legislative instrument that amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - Specification Under Subsection 84AAA(2). This instrument applies to pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS) established under the National Health Act 1953. It specifies the circumstances under which an early supply of a pharmaceutical benefit can occur, where an early supply is defined as a supply made within 20 days after a previous supply of the same pharmaceutical benefit to the same person, excluding supplies resulting from prescriptions originating from a hospital or day hospital facility. The instrument applies nationally across Australia and involves both the Commonwealth and the states and territories, given the administration of the PBS. The instrument specifies certain pharmaceutical items by drug or medicinal product, form, manner of administration, maximum quantity or number of units, and maximum repeats, with changes effective from 1 November 2009. The Minister makes these specifications based on advice from the Pharmaceutical Benefits Advisory Committee, which provides expert recommendations on which drugs should be available as pharmaceutical benefits. The instrument excludes supplies from hospitals or day hospitals and specifies that early supplies should not be taken into account when determining eligibility for a concession card or entitlement card, unless the supply is of an out-patient medication. This instrument is made under subsection 84AAA(2) of the Act, which authorises the Minister to specify pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act.

Key Provisions

The National Health (Pharmaceutical Benefits – Early Supply) Amendment November 2009 – specification under subsection 84AAA(2) instrument (F2009L04036) amends the list of pharmaceutical items eligible for early supply under the Pharmaceutical Benefits Scheme (PBS), as specified in section 84AAA(1) of the National Health Act 1953. This legislative instrument (subsection 84AAA(2)) specifies the pharmaceutical benefits that can be supplied early, provided they meet the criteria outlined in the Act. The early supply of a specified pharmaceutical benefit is defined as a supply made within 20 days after a previous supply of the same pharmaceutical benefit to the same person, excluding supplies resulting from prescriptions originating from hospitals or day hospital facilities (subsection 84AAA(1)). This legislative instrument amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) by adding new items and modifying existing ones. The Act imposes several obligations on the parties involved. The Minister is responsible for determining the form, manner of administration, maximum quantity, and number of repeats for pharmaceutical benefits listed under the PBS (subsection 85(2) to 85(6)). The Pharmaceutical Benefits Advisory Committee (PBAC) provides advice to the Minister regarding which drugs and medicinal preparations should be available as pharmaceutical benefits. The PBAC also makes recommendations about the pharmaceutical benefits to be specified in the instrument under subsection 84AAA(2) (subsection 101(3AA)). Pharmacists and medical practitioners approved to supply pharmaceutical benefits must comply with the patient charges set out in the Act (subsection 87(2)) and the payment amounts for early supply prescriptions (section 99). The Act outlines specific offences and penalties for breaches. However, the Explanatory Statement does not provide details on the maximum penalties for these offences. It is important to note that the Act regulates the supply and repeated supply of pharmaceutical benefits, including early supply, to ensure compliance with patient charges and payment amounts. The instrument also addresses the definition of "hospital" and "day hospital facility" under the Health Insurance Act 1973 and the National Health Act 1953, respectively. These definitions are relevant to the provisions concerning early supply and the exclusion of certain supplies from the early supply definition (subsections 84AAA(1), 3(1), and 4(1)). In summary, the National Health (Pharmaceutical Benefits – Early Supply) Amendment November 2009 – specification under subsection 84AAA(2) instrument amends the list of pharmaceutical items eligible for early supply under the PBS. It imposes obligations on the Minister and PBAC to determine the form, manner of administration, maximum quantity, and number of repeats for pharmaceutical benefits and to provide advice on early supply. The Act also regulates patient charges and payment amounts for early supply prescriptions, although specific penalties for breaches are not detailed in the Explanatory Statement.

Legal classification tags

Area of Law
Health Law
Pharmaceutical Law
Instrument
Legislative Instrument
Concepts
Definitions & Interpretation
Reporting & Disclosure Obligations
Enforcement Powers
Compliance Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.